↓ Skip to main content

Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy

Overview of attention for article published in International Journal of Hematology, January 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
23 Mendeley
Title
Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy
Published in
International Journal of Hematology, January 2015
DOI 10.1007/s12185-015-1750-z
Pubmed ID
Authors

Haruhito Totani, Shigeru Kusumoto, Takashi Ishida, Arisa Masuda, Takashi Yoshida, Asahi Ito, Masaki Ri, Hirokazu Komatsu, Shuko Murakami, Masashi Mizokami, Ryuzo Ueda, Akio Niimi, Hiroshi Inagaki, Yasuhito Tanaka, Shinsuke Iida

Abstract

Reactivation of hepatitis B virus (HBV) infection may occur in adult T-cell leukemia-lymphoma (ATL) patients with resolved HBV infection who receive monotherapy with the anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab. However, there is little evidence regarding the incidence and characteristics of HBV reactivation in ATL patients receiving systemic chemotherapy, including the use of this antibody. We conducted a retrospective study for 24 ATL patients with resolved HBV infection underwent regular HBV DNA monitoring to assess HBV reactivation in Nagoya City University Hospital between January 2005 and June 2013. With median HBV DNA follow-up of 238 days (range 57-1420), HBV reactivation (defined as the detection of HBV DNA) was observed in three (12.5 %) of 24 patients with resolved HBV infection. No hepatitis due to HBV reactivation occurred in those patients who were diagnosed with HBV DNA levels below 2.1 log copies/mL and who received antiviral drugs. Mogamulizumab was administered prior to HBV reactivation in two of three HBV-reactivated patients. In the mogamulizumab era, further well-designed prospective studies are warranted to estimate the incidence of HBV reactivation and to establish regular HBV DNA monitoring-guided preemptive antiviral therapy for such patients.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 22%
Student > Ph. D. Student 3 13%
Student > Master 3 13%
Other 2 9%
Professor 1 4%
Other 1 4%
Unknown 8 35%
Readers by discipline Count As %
Medicine and Dentistry 9 39%
Biochemistry, Genetics and Molecular Biology 2 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 9%
Immunology and Microbiology 1 4%
Agricultural and Biological Sciences 1 4%
Other 0 0%
Unknown 8 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2015.
All research outputs
#20,252,875
of 22,782,096 outputs
Outputs from International Journal of Hematology
#1,081
of 1,392 outputs
Outputs of similar age
#296,969
of 353,045 outputs
Outputs of similar age from International Journal of Hematology
#11
of 17 outputs
Altmetric has tracked 22,782,096 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,392 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,045 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.